The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2

T2DM (Type 2 Diabetes Mellitus) Clinical Trial

Official title:

An Open-label, Multiple Dose, Crossover Study to Evaluate the Drug-drug Interaction Between AJU-A51R1 and AJU-A51R2 in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04970940
• Other study ID #: 20DM10201
• Status: Completed
• Phase: Phase 1
• Start date: July 2, 2020
• Est. completion date: December 31, 2020

Study information

• Verified date: July 2021
• Source: AJU Pharm Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate a pharmacokinetic drug interaction between AJU-A51R1 and AJU-A51R2 in healthy male volunteers.

Description:

This study is to investigate drug-drug interaction between AJU-A51R1 and AJU-A51R2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 31, 2020
• Est. primary completion date: October 7, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Individuals whose age is over 19 and under 65 years old when visiting for initial screening test.

2. Body mass index(BMI) between 17.5~30.5 kg/m^2 and the body weight must be over 55 kg(men) or 45 kg(women) (Body mass index (BMI) = weight (kg) / height (m)^2) .

3. Individuals with no congenital or chronic disease in three years, no history of symptoms in internal treatment, or no knowledge in the area.

4. Due to the special characteristics of drugs, the participators must be qualified to do the clinical screening after examined through hematology test and blood chemistry analysis, urinary test, the electrocardiogram (ECG), and etc.

5. The participants must be volunteered and sign in an informed consent document proven by Chonbuk National University IRB before joining a study to show that he was given informed the purpose of tests and the special characteristics of drugs.

6. Individuals who agreed proper contraception during the study

7. The participants must have an ability and willingness to participate throughout the entire trials.

Exclusion Criteria:

1. Individuals with a medical evidence or a history (excluding dental history of periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune disease.

2. Individual who had a history of gastrointestinal related disease which can be affected the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's disease) or surgeries (except a simple appendectomy or herniotomy).

3. Individual who had following results after examination(a. ALT or AST > twice higher than Upper limit of normal value).

4. Individual Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (12%) (125 mL) = 12g).

5. Individual whose blood pressure < 90 or =160(systolic blood pressure) or < 50 or = 100(diastolic blood pressure).

6. Individuals who had been administered investigational product(s) from other clinical study or bioequivalence study within 180 days prior to the first dose of this study(except when subject have not taken investigational product(s)).

7. Individual who had a medical history of alcohol and drug abuses.

8. Individual who had taken a drug that has a control of metabolic rate (activation or inhibition) in 30 days before the first taking of clinical testing drug.

9. Individual who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders.

10. A person who is not determined unsuitable to participate in this test by the researchers.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• T2DM (Type 2 Diabetes Mellitus)

Intervention

Drug:
• Treatment A
AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days
• Treatment B
AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days
• Treatment C
AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days

Locations

Country	Name	City	State
Korea, Republic of	Min-gul Kim	Jeonju	Korea

Sponsors (1)

Lead Sponsor	Collaborator
AJU Pharm Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUCt of AJU-A51R1 and AJU-A51R2	Area Under Curve tau	predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours post-dose
Primary	Css,max of AJU-A51R1 and AJU-A51R2	Cmax, steady state	predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours post-dose